Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Group (CAN) has signed a five year supply agreement with Pure Cann New Zealand
  • Under this agreement, Cann will be the main production and manufacture partner for Pure Cann
  • Pure Cann is focusing on creating a business to supply medicinal cannabis to patients in New Zealand
  • This follows New Zealand’s new laws around medicinal cannabis that came into place earlier this month.
  • These new rules are to make it easier for doctors to prescribe medicinal cannabis and for manufacturing and cultivating licenses to be granted
  • Cann is up slightly on the market today, selling shares for 87.5¢ per share

Cann Group (CAN) has signed a five year supply agreement with Pure Cann New Zealand.

Under this agreement, Cann will be the primary production and manufacture partner for Pure Cann.

Pure Cann is building a patient-centric medicinal cannabis business and is focused on supplying medicinal cannabis to patients in New Zealand.

The country’s medicinal cannabis new rules came into effect on April 1 2020 and were put in place to make it easier for doctors to prescribe medicinal cannabis and for manufacturing and cultivating licenses to be granted.

Cann will supply products manufactured from cannabis flowers grown at Cann Group’s existing facilities, including the Mildura facility.

Cann, through its subsidiary Botanitech, holds a 3.9 per cent interest in Pure Cann. The company purchased the holding for NZ$1 million. This new agreement will also allow Cann to increase its holding to 7.7 per cent.

To receive this holding the company will purchase a further NZ$1 million in Pure Cann’s shares.

“Our ability to secure supply agreements with quality long-term partners helps support the value of our expansion plans and reinforces Cann Group as a leader in cannabis genetics, cultivation and manufacture,” Cann Group CEO Peter Crock, said.

The existing technical service agreement (TSA) between the companies has also been extended until April 2026.

Cann is up slightly on the market today, selling shares for 87.5¢ per share at market close.

CAN by the numbers
More From The Market Online

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…

Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection

Telix Pharmaceuticals has been granted Fast Track designation by the FDA for its brain cancer imaging…

Atomo Diagnostics orders HIV self-test kits for third world countries

Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued…

Imugene expands study for bile tract cancer patients

Imugene will be expanding its trial to treat gastrointestinal cancers - including bile tract cancer -…